Colorectal cancer metastatic
RecruitingStudy of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer
Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabFluorouracil+4
France- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Fondation Franc.Cancerologie Digestive








